Clinical Trials · NCT02729766

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Name: Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2/Phase 3Desmopressin

Phase: Phase 2/Phase 3
Recruitment status: Completed
Sponsor: University Hospital, Basel, Switzerland
Enrollment: 15
Start date: Mar 2016
Locations: 1 site, Switzerland
Primary endpoint: The primary outcome is the area under the curve (AUC) of the serum sodium concentration between time points 2 and 8 hours after administration of the study drug.

View Desmopressin compound reference